Background
==========

Although significant advances have been achieved in recent years in experimental research, diagnosis, and treatment of cancer, gastric cancer (GC) remains the second most frequent cause of cancer death after lung cancer worldwide, and exhibits a poor prognosis \[[@B1],[@B2]\]. Surgical resection plus extended lymph node dissection comprises the primary method of curative intent for localized gastric cancer, however, the 5-year survival rate remains unsatisfactory \[[@B3],[@B4]\]. Peritoneal dissemination is one of the principal reasons for the recurrence and metastasis of gastric cancer in the peritoneal cavity, and it has been reported to be complicated and difficult to treat in recent years \[[@B5]\]. The peritoneal seeding of gastric cancer (GC) exhibits a high risk for patients who receive surgery alone, and systemic chemotherapy exhibits no significant effect \[[@B6]\]; the origins may be the free tumor cells from the primary gastric cancer that remain following surgery, or micrometastases in the peritoneal cavity \[[@B7]\].

In spite of the use of both systemic chemotherapy and radiation therapy, the survival rate of patients with advanced gastric cancer remains unsatisfactory. Adjuvant intraperitoneal chemotherapy (IPC) is recognized as an effective method to control peritoneal dissemination in GC patients who have undergone resection of the primary cancer \[[@B8],[@B9]\]. Intraperitoneal chemotherapy is used to achieve longer survival by wiping out the mircometastases in the abdominal cavity and free tumor cells left after surgery that could not be cleaned up by intravenous chemotherapy. A number of studies have investigated whether intraperitoneal chemotherapy exhibits an effect on patients with advanced gastric cancer, such as Xu DZ et al. \[[@B10]\] and Yan TD et al. \[[@B8]\], and all reports reached a positive conclusion regarding improved survival rate. Recently, hyperthermia has been developed as an anticancer therapy, and has been demonstrated to exhibit a direct cytotoxic effect on tumor cells in the peritoneal cavity in conjunction with some anticancer chemotherapeutic agents \[[@B11]\]. Since Spratt et al. \[[@B12]\] reported the use of hyperthermic intraperitoneal chemotherapy for the treatment of peudomyxoma peritonei, several positive reports regarding hyperthermic intraperitoneal treatment for gastric cancer have been published, but the results were not unified. The purpose of our meta-analysis was to evaluate the effectiveness, safety, and preventive effects of hyperthermic intraperitoneal chemotherapy for patients with advance gastric cancer who received radical surgery through analysis of the results of randomized controlled trials.

Methods
=======

Search strategy
---------------

An electronic search was applied to PubMed (up to November 2011), EMBASE (up to November 2011), Cochrane Database of Systematic Reviews (CDSR), and Cochrane Central Register of Controlled Trials (CCTR) (up to November 2011). Both published and unpublished trials were included, and no search restrictions were imposed. Furthermore, the reference lists of all selected studies were reviewed for further identification of potential relevant articles.

Selection criteria
------------------

Inclusion criteria included all articles concerning patients with gastric cancer who were allocated randomly to receive surgery associated with intraperitoneal hyperthermic chemotherapy versus surgery without intraperitoneal hyperthermic chemotherapy. The advanced gastric cancer of the patients consisted of macroscopic serosal invasion without distant metastases or peritoneal carcinomatosis. Studies were limited to human trials, and there was no language restriction. If centers published duplicate trials with an increased number of patients or follow-up time period, we utilized the most complete reports in the meta-analysis.

Date extraction and critical appraisal
--------------------------------------

Two reviewers (one clinical, Jingxu Sun, and one non-clinical, Xiaowan Chen) reviewed each article independently, and discrepancies between the two reviewers were resolved through discussion and consensus. The authors, publication years, country of investigators, sample size, total numbers for survival and death, the different detailed chemotherapy regimens, follow-up period, curative effects, adverse events, surgery plans, and the peritoneal recurrence status of each trial were extracted (Table [1](#T1){ref-type="table"}). The quality of the trials was evaluated using Jadad quality scores \[[@B13]\], and included secure methods for randomization, allocation concealment, patient and observer blinding, and loss to follow-up. The studies were divided into a low quality group (score \< 4) and high quality group (score ≥ 4) (Table [2](#T2){ref-type="table"}).

###### 

Basic characteristics of trials included in the present study

                   **Author**          **Publication years**   **Country**                   **Chemotherapy regimens**                    **Chemotherapy group (number of death/total)**   **Surgery group (number of death/total)**   **Follow-uptime (months)**   **Chemotherapy group (number of R0/total)**   **Surgery group (number of R0/total)**   **Peritoneal recurrence in chemotherapy group**   **Peritoneal recurrence in surgery group**
  -------- -------------------------- ----------------------- ------------- ------------------------------------------------------------ ------------------------------------------------ ------------------------------------------- ---------------------------- --------------------------------------------- ---------------------------------------- ------------------------------------------------- --------------------------------------------
   **1**      **Koga S**\[[@B16]\]             1988               Japan              8-10 μg/ml MMC, 8-12 L, 50-60 min, 44-45°C                                4/26                                          7/21                                  30                                  26/26                                      21/21                                          NA                                              NA
   **2**    **Hamazoe R**\[[@B17]\]            1993               Japan              10 μg/ml MMC, 10-12 L, 50-60 min, 48-50°C                                18/42                                          22/40                                 77                                  40/42                                      35/40                                          7\*                                            13\*
   **3**    **Fujimura T**\[[@B18]\]           1994               Japan            30 mg MMC + 300 mg CDDP, 6-8 L,60 min, 41-42°C                              7/22                                          14/18                                 36                                   NA                                          NA                                           2\*                                            4\*
   **4**    **Ikeguchi M**\[[@B19]\]           1995               Japan              8-10 μg/ml MMC, 8-10 L, 50-60 min, 44-45°C                               38/78                                          52/96                                 60                                  78/78                                      96/96                                         27\*                                            38\*
   **5**    **Fujimoto S**\[[@B20]\]           1998               Japan               10 μg/ml MMC, 3-4 L, 120 min, 44.5-45°C                                 27/71                                          36/70                                 96                                  67/71                                      65/70                                          1\*                                            16\*
   **6**    **Yonemura Y**\[[@B21]\]           2001               Japan            30 mgMMC + 300 mg CDDP, 6-8 L, 60 min, 42-43°C                             19/48                                          27/47                                 60                                  48/48                                      47/47                                           6                                              7
   **7**      **Zuo Y**\[[@B22]\]              2004               China      80-100 mg CDDP + 1000 mg 5-FU + 5 mg, 2 L,60 min, 41--43°C                        8/46                                          14/36                                 36                                   NA                                          NA                                           NA                                              NA
   **8**      **Wei G**\[[@B23]\]              2005               China               1000 μg/ml 5-UF, 4-5 L, 60 min, 43-45°C                                 21/42                                          25/46                                 36                                  40/49                                      49/55                                          NA                                              NA
   **9**     **Zhang GY**\[[@B24]\]            2007               China            30 mg MMC + 300 mg CDDP, 2 L, 30 min, 42-45°C                              44/92                                         75/120                                 60                                  92/92                                     120/120                                         13                                              45
   **10**    **Deng HJ**\[[@B25]\]             2009               China             300-500 μg/ml 5-FU, 3 L, 60-90 min, 42-43°C                               18/44                                          27/41                                 60                                  44/44                                      41/41                                          NA                                              NA

\*: The number of patients dead from peritoneal recurrence.

###### 

Quality assessment of trials included in the present study

                   **Author**          **Randomization**   **Blind**   **Allocation concealment**   **Withdrawal and dropout**   **Jadad Scroe**
  -------- -------------------------- ------------------- ----------- ---------------------------- ---------------------------- -----------------
   **1**      **Koga S**\[[@B16]\]      without details       no             well reported                well reported                 4
   **2**    **Hamazoe R**\[[@B17]\]     without details       no             well reported                well reported                 4
   **3**    **Fujimura T**\[[@B18]\]    without details       no            without details               well reported                 3
   **4**    **Ikeguchi M**\[[@B19]\]    without details       no                unclear                   well reported                 2
   **5**    **Fujimoto S**\[[@B20]\]    without details       no                unclear                   well reported                 2
   **6**    **Yonemura Y**\[[@B21]\]    without details       no            without details               well reported                 3
   **7**      **Zuo Y**\[[@B22]\]       without details       no                unclear                   well reported                 2
   **8**      **Wei G**\[[@B23]\]        well reported        no             well reported                well reported                 5
   **9**     **Zhang GY**\[[@B24]\]      well reported        no             well reported                well reported                 5
   **10**    **Deng HJ**\[[@B25]\]       well reported        no             well reported                well reported                 5

Statistical analysis
--------------------

The end-point of the meta-analysis was overall survival, defined as the time from treatment to the last follow-up or death. Results regarding the overall survival in the meta-analysis were reported as risk ratio (RR) with 95% confidence interval (CI). The heterogeneity between the trials and groups was studied using the *χ*^2^ test (or Cochran *Q* statistic) for statistical significance, and measured with *I*^2^ statistic for degree of heterogeneity \[[@B14],[@B15]\]. The *I*^2^ statistic is derived from the *Q* statistic (*Q-df*/*Q* × 100). *I*^2^ \< 25 was considered to indicate low heterogeneity and *I*^2^ \>50% indicated a large degree of heterogeneity. If there was major heterogeneity, a random-effect model was used, and if there was no conspicuous heterogeneity, we chose a fixed-effect model for meta-analysis. The P value threshold for statistical significance was set at 0.05 for effect sizes. Publication bias was tested using the funnel plot. All statistical analysis was performed by RevMan 5.1 software, which was provided by Cochrane Collaboration.

Results
=======

Eligible trials
---------------

We searched a total of 280 studies. Through screening of the titles and reading the abstracts, 31 potentially relevant reports were identified that included surgery plus HIPC versus surgery alone. Of these 31 articles, only ten randomized trials were fit the selection criteria \[[@B16]-[@B25]\] and included in our study. The selection procedure was further summarized in Figure [1](#F1){ref-type="fig"}. The 1062 gastric cancer patients enrolled in the studies were divided into the HIPC group (n = 518) and control group (n = 544), shown in Table [1](#T1){ref-type="table"}. Of the ten trials, all of the investigators were from Asia: six were from Japan \[[@B16]-[@B21]\] and four were from China \[[@B22]-[@B25]\]. The quality of the included trials was evaluated according to the Jadad-scale (Table [2](#T2){ref-type="table"}), and three trails \[[@B20],[@B21],[@B23]\] were low quality according to the scores (\< 4 scores).

![Selection of included trials.](1471-2407-12-526-1){#F1}

Overall survival rates
----------------------

The overall survival rate of the 1062 patients in the ten studies was shown in Figure [2](#F2){ref-type="fig"}\[[@B16]-[@B25]\] (518 in the HIPC group and 544 in the control group). Seven trials used MMC as the primary drug in HIPC \[[@B15]-[@B21]\] and three used 5-FU.

![Risk Ratios for overall survival rates of all 10 randomized controlled trials.](1471-2407-12-526-2){#F2}

Thus, we created two subgroups for analysis: MMC subgroup and 5-FU subgroup. As a result, significant survival improvements were found in the HIPC group compared to the control group, as well as in the MMC subgroup (RR = 0.75, 95%CI 0.65-0.86; P \< 0.00001; fixed-effect model), and in the 5-FU group (RR = 0. 69, 95%CI 0.52-0.90; P \< 0.00001; fixed-effect model). There was no obvious statistical heterogeneity in the trials. All trials analysis provided similar results (RR = 0. 73, 95%CI 0.64-0.83; P \< 0.00001; fixed-effect model) without statistical heterogeneity (*I*^2^ = 0%). Four trials \[[@B19],[@B22],[@B24],[@B25]\] utilized systemic chemotherapy after surgery for both the HIPC and control groups. We used additional analysis to obtain results that were identical in the group without systemic chemotherapy (RR = 0.71, 95%CI 0.59-0.87; P \< 0.00001; fixed-effect model) and the group with systemic chemotherapy (RR = 0.75, 95%CI 0.63-0.89; P \< 0.00001; fixed-effect model) (Figure [3](#F3){ref-type="fig"}). Sensitivity analysis was performed without the low quality trials and the results were the same (RR = 0.74, 95%CI 0.64-0.86; P \< 0.00001).

![Risk Ratios for overall survival rate of trials with or without systemic chemotherapy.](1471-2407-12-526-3){#F3}

Peritoneal dissemination
------------------------

There were six studies \[[@B17]-[@B21],[@B24]\] that reported recurrence in the abdominal cavity (Table [1](#T1){ref-type="table"}). All of these six trials described the occurrence of peritoneal local-regional recurrence, but four of them \[[@B17]-[@B20]\] only supplied the number of patients who died from peritoneal recurrence. Hamazoe R \[[@B17]\], Fujimura T \[[@B18]\], Ikeguchi M \[[@B19]\] and Fujimoto S \[[@B20]\] all supplied the recurrence numbers of patients who died. In Hamazoe R's trial, 7 of 18 patients in the HIPC group died due to peritoneum local-regional recurrence, and 13 of 22 patients died in the control group. In Fujimura T's trial, 2 of 7 patients in the HIPC group died due to peritoneum local-regional recurrence, and 4 of 14 patients died in the control group. In Ikeguchi M's trial, 27 of 38 patients in HIPC group died due to peritoneum local-regional recurrence, and 38 of 52 patients died in the control group. Also, in Fujimoto S's trail, 1 of 27 patients in the HIPC group died due to local recurrence, and 16 of 36 patients died in the control group. We explored the relationships among these four trials, and attempted to perform meta-analysis. However, we found that there was significant heterogeneity (P = 0.02, *I*^*2*^ = 62%); thus, we described the above four trials.

The remaining two trials reported the recurrence of all patients, and we used these data for analysis. Figure [4](#F4){ref-type="fig"} showed that HIPC exhibited a lower recurrence rate compared to the control group (RR = 0.45, 95%CI 0.28-0.72; P = 0.001; fixed-effect model), and the heterogeneity was not very significant between these trials. Thus, HIPC may exhibit a significant preventive effect on patients who received surgery for advanced gastric cancer.

![Risk Ratios for peritoneal dissemination.](1471-2407-12-526-4){#F4}

Adverse events
--------------

The adverse events included bone marrow suppression, anastomotic leak, bowel fistula, adhesive ileus, and liver disfunction. In our study, five trials \[[@B20],[@B21],[@B23]-[@B25]\] reported bone marrow suppression: one patient in the HIPC group and none in the control group in Yonemura Y's trial, two patients in HIPC group and one in the control group in Wei G's group, and six patients in HIPC group and four patients in the control group in Deng HJ's study; in the two remaining trials there were no patients in either the HIPC group or control group who exhibited bone marrow suppression. The RR value was 1.68 (95%CI 0.62-4.58; P = 0.31; fixed-effect model) and there were no statistically significant differences between the HIPC and control groups. Five studies \[[@B16],[@B17],[@B20],[@B21],[@B24]\] reported anastomotic leak: in Koga S's group there was one patient in the HIPC group and two patients in the control group, in Hamazoe R's group there were two patients in the HIPC group and three patients in the control group, and in Ynoemura Y's trial there was one patient in the HIPC group and two patients in the control group. The RR was 0.52 (95%CI 0.16-1.73; P = 0.29; fixed-effect model) and had no statistical significance. Three trials \[[@B20],[@B21],[@B24]\] reported the occurrence of bowel fistula: there were two patients in each group of Fujimoto S's trial, one patient in the HIPC group and no patients in the control group in Ynemura Y's report. The RR was 1.38 (95%CI 0.28-6.85; P = 0.70; fixed-effect model) and had no statistical significance. Three trials \[[@B16],[@B17],[@B22]\] recorded adhesive ileus, in which Koga S reported one patient in the HIPC group and two patients in the control group, Zuo Y described two patients in the HIPC group and one patient in the control group. The RR was 0.79 (95%CI 0.17-4.12; P = 0.77; fixed-effect model) and there was no statistical significance. Similarly, five studies reported the occurrence of liver dysfunction: in Wei G's trial there were two patients in each group, there were three patients in the HIPC group and two patients in the control group in both trials reported by Zhang GY and Deng HJ, and the RR was 1.47 (95%CI 0.52-4.12; P = 0.47; fixed-effect model). In the other trials, there were no reports regarding the adverse events, or there were statistics of adverse events but no patients specifically cited (Figure [5](#F5){ref-type="fig"}). The adverse event results we obtained all exhibited no statistical significance. Because of the different research aims of the trials, the different adverse events were chosen. In the future, more comprehensive evidence is warranted.

![Risk Ratios for adverse events.](1471-2407-12-526-5){#F5}

Discussion
==========

The survival rate of patients with gastric cancer has improved along with the improvement of surgical procedures \[[@B26]\]. However, many patients who have received gastric cancer resection still have suffered local-regional or peritoneal recurrence. Dissemination of free tumor cells through blood or lymph into the abdominal cavity has been considered one of the most common causes of peritoneal dissemination of gastric cancer \[[@B27]\]. Thus, it is very important to eliminate the free tumor cells in the abdominal cavity in order to improve survival rates. Intraperitoneal chemotherapy for intraperitoneal cancer was first suggested in the 1950s \[[@B28]\]. Intraperitoneal chemotherapy is able to kill the free tumor cells left behind after surgery that were not eliminated by traditional systemic chemotherapy. Hyperthermic intraperitoneal chemotherapy was first performed as a clinical trial to investigate removal of intraperitoneal tumor cells in 1980 \[[@B12]\]. HIPC washes out intraperitoneal free tumor cells using a large massive liquid, and damages cancer cells or micrometastases directly due to the heat sensitivity of tumor cells \[[@B17],[@B29]\]. Thus, HIPC combined with surgery has been used to control peritoneal metastasis in gastric cancer; however, there is still no solution as to whether it exhibits an effect on long-term survival and prevention of peritoneal recurrence.

The purpose of a meta-analysis is to supply an exhaustive and neoteric summary of all relevant RCTs concerning the topic, and to provide guidance for future clinical work. Our present meta-analysis demonstrated the effects of HIPC in correlation with different chemotherapy regimens for patients who had received advanced gastric cancer tumor resection in order to improve the survival rate. In a study conducted by Xu DZ et al. \[[@B10]\], intraperitoneal chemotherapy after cancer was demonstrated to be beneficial to patients with gastric cancer. Similar results were reported with six RCTs on the topic by Yan TD et al. \[[@B8]\] in 2007, in which it was demonstrated that hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) with or without early postoperative intraperitoneal chemotherapy (EPIC) following resection of gastric cancer improved survival. Sensitivity analyses (Figure [6](#F6){ref-type="fig"}) and funnel plot analyses concerning potential publication bias (Figure [7](#F7){ref-type="fig"}) were also performed to confirm the reliability of our research results. The publication bias may be a problem for meta-analysis, but we did not find this bias in our study.

![Sensitivity analysis for overall survival: high-quality studies (Jadad score ≥≥≥ 4).](1471-2407-12-526-6){#F6}

![Funnel plot analysis of potential publication bias.](1471-2407-12-526-7){#F7}

In the past, many researchers have reported that approximately 50% of patients who received resection of advanced gastric cancer exhibited a local-regional recurrence in their abdominal cavity and a poor prognosis \[[@B30],[@B31]\]. However, because few RCTs reported peritoneal recurrence, the earlier studies could not be utilized to analyze the relationship between the HIPC and control groups regarding local-regional recurrence. We included six trials that reported peritoneal local-regional recurrence, but only two trials supplied the recurrence rate for all patients. The results of our meta-analysis indicated that HIPC could potentially allow for a better prognosis in patients who underwent resection for advanced gastric cancer compared to the control group, and may play a role in the prevention of peritoneal local-regional recurrence. The other four trials, except for the report by Ikeguchi M \[[@B19]\], all indicated that peritoneal recurrence was more frequent in the control group compared to the HIPC group. Additionally, Ikeguchi M reported that HIPC potentially prevents peritoneal metastases among patients with no lymph node metastases. We also counted the type of radical surgery received by the patients (Table [1](#T1){ref-type="table"}), and a great majority of patients received R0 resection. It was interesting that patients of the two trails processed in meta-analysis were all received R0 radical resection. Thus, for gastric cancer patients (serosal invasion) with R0 resection but high probability of peritoneal recurrence, HIPC may play an important role. However, the small number of trials that have reported total peritoneal recurrence is a problem that we encountered; the study of a greater number of interrelated studies is awaited.

The adverse events in the HIPC and control groups were also described in our research. The independent effects of hyperthermia for cancer cells is strongly increased when the temperature range is 42.5°C to 43.0°C, but because selective heating of only tumor cells is very difficult the injury to normal tissues is also increased \[[@B18]\]. In Yan TD's \[[@B8]\] study, he reported that HIIC with or without EPIC after resection of gastric cancer increased the risk of intra-abdominal abscess and neutropenia. Few clinical trials have previously described the side effects of HIPC, and in various reports differing data were supplied. Our results indicated that there were no statistically significant differences regarding adverse events between the HIPC group and the control group. However, further comprehensive proof is needed to confirm this.

Over the past couple of decades, several investigators reported that HIPC significantly improved the survival rate in serosa-invasive gastric cancer patients. This finding was due to the prevention of early postoperative peritoneal metastasis \[[@B26]\]. However, although our findings indicated that the survival rate might be generally significantly improved following HIPC, the individual optimal regimen remains unclear, and further studies are warranted. Also, the effectiveness of HIPC potentially depends on the diameter and depth of the micrometastasis, because heat or drugs cannot reach the cancer cells \[[@B16],[@B32],[@B33]\]. However, there were several adverse events after the treatment of HIPC that were not avoided as common complications of chemotherapy. In spite of the Jadad-scale was used to assess the investigations and all articles included in the studies were RCT, the quality of RCT studies cannot be fully accessed. The bias caused by quality of included articles may be a factor which may influence the result of the study. Although the Jadad-scale is visualized and pellucid, a consummate and exhaustive appraisal procedure is still awaited. Additionally, all of the trials included in this analysis were from Asia, particularly China and Japan. Thus, whether HIPC is useful for other patients of the world remains to be seen in further investigations.

Conclusion
==========

In conclusion, our meta-analysis demonstrated that HIPC potentially improves the overall survival rate of patients who underwent resection for advanced gastric cancer, and potentially functions by preventing local recurrence. In the future, higher quality studies, superior patient selection, and well designed multi-center RCTs are awaited.
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